Glaukos (GKOS)

The company is widely associated with micro-invasive glaucoma surgery, or MIGS. Its iStent family of devices is designed to improve aqueous fluid outflow and lower intraocular pressure in patients with glaucoma. Commercial products include iStent, iStent inject W, and iStent infinite, each aimed at different clinical needs within glaucoma management. These devices are used by ophthalmic surgeons and are part of a broader shift toward less invasive approaches for treating the disease.

Glaukos has also expanded into drug delivery. iDose TR is an intracameral implant intended to provide extended delivery of glaucoma medication from inside the eye, offering an alternative for patients who struggle with adherence to topical drops. This product reflects the company’s strategy of combining device engineering with pharmaceutical therapy.

In corneal health, Glaukos markets a bio-activated pharmaceutical therapy for keratoconus, a rare disorder that can cause progressive thinning and distortion of the cornea. The company’s pipeline also includes programs targeting additional eye diseases.

For investors, Glaukos is a specialized growth company in ophthalmic innovation. Its differentiation lies in proprietary implantable devices, sustained drug-delivery technology, and a commercial focus on diseases where long-term management, patient compliance, and surgical outcomes are critical.